六味补气胶囊在肺气虚型慢性阻塞性肺病稳定期治疗中的临床疗效

Clinical Efficacy of Liuwei Buqi Capsule in Reatment of COPD Patients in Stable Phase

目的:观察六味补气胶囊对慢性阻塞性肺病(COPD)稳定期患者生活质量及肺功能的影响,以期为此类疾病的治疗提供参考。方法:分析2015年1月—2016年7月在本院接受就诊的COPD稳定期患者的临床资料。依据治疗药物的不同,将患者分为观察组(六味补气胶囊+常规治疗)及对照组(常规治疗)。治疗前后对两组患者行圣乔治呼吸疾病问卷(SGRQ)评分,对患者的生活质量进行评价,同时检测肺功能及外周血炎性因子水平。结果:本研究共纳入观察组38例,对照组38例。两组患者在治疗后呼吸症状、活动受限、疾病影响、生活质量评分均比治疗前显著降低,差异具有统计学意义(P<0.05);并且治疗后观察组在各方面均低于对照组,差异具有统计学意义(P<0.05)。治疗后两组患者FVC、FEV1、FEV1/FVC显著升高,差异具有统计学意义(P<0.05);组间比较观察组患者肺功能指标改善较为明显,差异具有统计学意义(P<0.05)。两组患者治疗后外周血TNF-α、CRP及IL-6水平均显著降低,差异具有统计学意义(P<0.05),但观察组患者低于对照组患者,差异具有统计学意义(P<0.05)。结论:六味补气胶囊可明显提高气虚型COPD稳定期患者的生活质量和肺功能,值得临床推广使用。

Objective：Our study was aimed to analyze the clinical efficacy of Liuwei Buqi Capsule in the treatment of COPD patients in stable phase.Methods：Clinical data of COPD patients in stable phase received treatment at our hospital from 2015 to2016 was analyzed.Patients were divided into two groups by therapeutic methods.Group A：Liuwei Buqi Capsule ＋ conventional therapy.Group B：conventional therapy.Results：A total of 76 patients were analyzed,Group A 38 cases,Group B 38 cases.After treatment,Group A patients got a lower SGRQ scores than that of Group B patients（P〈0.05）.Both of the two groups got significant improvement in FVC,FEV1 and FEV1/FVC（P〈0.05）,but these indexes were more higher in Group A when compared with those of Group B（P〈0.05）.After treatment,Group A patients got lower levels of TNF-α,CRP and IL-6 than those of Group B.The difference was statistically significant（P〈0.05）.Conclusion：Liuwei Buqi Capsule can improve the clinical efficacy for COPD patients in stable phase,including the lung function and living quality.